Let's Win Pancreatic CancerPancreatic

Using Tumor Tissue Samples to Break Down Assumptions About Pancreatic Cancer (Part 1/3)

In short

Physician-scientist Dr. Christine Iacobuzio-Donahue explains how tissue samples collected after a patient's death — through rapid research autopsy programs — are revealing new truths about how pancreatic cancer develops and spreads. Her team's findings challenge common assumptions, including the belief that pancreatic cancer spreads rapidly, and point toward real possibilities for earlier detection and more targeted treatment.

  • •Pancreatic cancer takes at least a decade to develop from its earliest form to a life-threatening stage, which means there may be a window for earlier detection — ask your care team what screening or monitoring options apply to you.
  • •The same genetic mutations that drive the original tumor also drive tumors that have spread, meaning a targeted treatment may work on both — worth discussing with your oncologist when reviewing treatment options.
  • •Metastatic tumors show additional epigenetic changes, and drugs targeting those changes are being studied — ask whether any clinical trials involving epigenetic therapies are relevant to your situation.
  • •Tissue donation programs like the Last Wish Program at Memorial Sloan Kettering allow patients to contribute to research after death — if this is something you or a loved one wants to consider, ask your care team how to learn more.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

Physician-scientist Dr. Christine Iacobuzio-Donahue has made good come from tragedy. She was just 10 years old when her dad died of metastatic colon cancer, six months after he received his diagnosis. “I was always aware of metastases since I was young, even before I really knew what it was,” she says. “I couldn’t imagine the concept of a patient being given a terminal diagnosis, and I knew I wanted to study this thing called metastasis.

” It’s a lofty goal, but one she is well-primed to study. As Director of the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), in New York, Iacobuzio-Donahue is researching the evolutionary mechanisms of cancer, specifically pancreatic cancer.

And when she is not in her lab, conducting research with her team, or presenting at or helping to chair various conferences, you can find her leading MSKCC’s Last Wish Program , which allows people to donate their tumor tissues after they die. It’s similar to a program she helped develop during her tenure at Johns Hopkins. Iacobuzio-Donahue has hundreds of peer-reviewed publications, numerous grants, and numerous awards.

In 2019, she added to her awards by being named recipient of the Ruth Leff Siegel Award , presented by the Siegel family and the Pancreas Center of Columbia University Irving Medical Center , New York. The Center has been entrusted by the Siegel family to identify the investigator, or team of investigators, who has had the most impactful contribution to the understanding, treatment, and advancement of pancreatic cancer over the past year.

The members of the Ruth Leff Siegel Award committee select an awardee outside of Columbia who will receive a $50,000 cash prize. A second award of $25,000 will recognize a faculty member within Columbia. , the Clyde and Helen Wu Professor of Chemical and Systems Biology. “I have to say I’m really excited about this and I’m really looking forward to it,” Iacobuzio-Donahue says.

“I remember being told early on that pancreatic cancer is a waste of my time and effort because there’s nothing that can be done. But the truth is you can’t do anything if you don’t put in the effort. I just want to jump in and do what is most important and most helpful. And I don’t and will never believe pancreatic cancer is automatically a death sentence.

” Finding Those Answers In trying to find those answers, Iacobuzio-Donahue and her team rely on the rapid research autopsy. The idea behind the rapid research autopsy protocols in pancreatic and other cancers is to obtain tissues from cancers quickly after death, before those tissues start to degrade, she explains. Then, using sophisticated gene technologies, “we can try to figure out just how pancreatic cancer survives,” she says.

“This is a disease that manages to survive every single drug that’s thrown at it, and the tissues have the answers. But it has to be said that we can’t find those answers without the incredible altruism shown by patients and their families. ” Rapid autopsy programs have many benefits for researchers.

These programs allow researchers to analyze tumors they couldn’t access while a patient is alive, help answer fundamental questions about why some patients respond to treatment while others don’t, and why treatments eventually stop working for many patients. But for Iacobuzio-Donahue, one of the most important aspects of the research autopsy is that it can help explain metastases, the deadly march of cancer cells spreading throughout the body.

“No matter how you look at it cancer is a disease of evolution,” she explains. “When we study the tissues post-mortem we can learn how metastases are different, most importantly how tumors that have spread are different from the tumor where the cancer started.

” In a paper published in September 2019 in the journal Nature , called “ Cancer Biology As Revealed by the Research Autopsy ,” she and her colleagues make a strong case as to how the research autopsy provides the best means to allow multi-regional sampling of a cancer that isn’t possible in traditional resections or biopsies in living patients.

And although the rapid research autopsy may not seem like a topic that engenders excitement, the opposite is true. Iacobuzio-Donahue’s work is significantly cited and fellow researchers are quick to point out that they couldn’t conduct their own studies without the tissue and research provided by labs like hers.

And if social media is any indication, Iacobuzio-Donahue’s presentation at the 2019 AACR pancreatic cancer conference on “Multimodal evolutionary dynamics of pancreatic cancer,” along with her Nature review article, were met with rave reviews. “I’m really happy about that because some images in my PowerPoint presentation kind of screwed up,” she laughs.

Breaking Down Assumptions The bulk of Iacobuzio-Donahue’s work is “to break down assumptions” about pancreatic cancer, she says. Some of her and her colleagues’ findings of which she is most proud upend the conventional wisdom that pancreatic cancer is so lethal because it spreads so quickly. Rather, they found that it takes at least a decade from when pancreatic cancer first forms for it to become deadly.

The team analyzed tissue samples taken post-mortem from patients with pancreatic cancer. They identified what are called “distinct subclones” of malignant cells present in the primary tumor before those cells spread to other body organs. A distinct subclone refers to the heterogeneity of tumors—pancreas tumors can be made up of many subpopulations of cells, each of which is characterized by a unique profile of gene variants.

Simply, when pancreatic cancer spreads to any organ, such as the liver or the lungs, those tumors are different than the tumor that started it all in the pancreas. By using a special algorithm, the team estimated the length of time to metastases. “For patients, what that really means is there is the opportunity for early detection, and prevention,” she notes.

Because of this tumor heterogeneity, conventional wisdom also assumed so-called driver mutations (mutations that promote growth and spread) were different. But Iacobuzio-Donahue and colleagues from Johns Hopkins and other sites found that it’s actually the same mutations that are involved in driving both the primary tumor and the spread of the tumor.

“What this means is that targeted treatments in metastatic disease could potentially work on the primary tumor and the tumors that have spread,” she says. She adds that they used tumor sequencing data on patients who never received treatment. Therefore, the multi-site team could study and gain unique insights on the natural course of pancreatic cancer since chemotherapy and radiation therapy alter cancer behavior.

In a related study, the researchers also found that metastatic tumors had additional epigenetic changes that could potentially be amenable to another treatment. ” They don’t actually change the DNA sequence. Drugs targeting these epigenetic changes are now being studied in cancer treatment. “Biology influences everything after the diagnosis,” says Iacobuzio-Donahue. ” And like other physician-scientists, she is hopeful.

“I really think the advances in pancreatic cancer are happening so quickly that I have to believe in my heart and my gut that if science doesn’t cure it, we will absolutely be able to provide long- term survival for patients. “It’s a bad disease. But it’s got an Achilles heel.

Highlights

from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.